

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – September 11, 2019 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum – See Appendix A

- A. Acknowledgment of Speakers for Public Comment
- B. Changes to Public Comment Procedure

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix B

- A. July 10, 2019 DUR Minutes – Vote
- B. July 10, 2019 DUR Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Muchmore, Chairman:

4. Action Item – Nomination of Drug Utilization Review (DUR) Board Officers

- A. Nominations of DUR Board Chair and Vice Chair – Vote

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence Program Update – See Appendix C

- A. Pharmacy Helpdesk Activity for July 2019
- B. Medication Coverage Activity for July 2019
- C. Pharmacy Helpdesk Activity for August 2019
- D. Medication Coverage Activity for August 2019
- E. Chronic Medication Adherence Program Update

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Zolgensma® (Onasemnogene Abeparvovec-xioi) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

7. Action Item –Vote to Prior Authorize Bryhali™ (Halobetasol Propionate 0.01% Lotion), Duobrii™ (Halobetasol Propionate/Tazarotene 0.01%/0.045% Lotion), and Lexette™ (Halobetasol Propionate 0.05% Foam) and to Update the Topical Corticosteroids Product Based Prior Authorization Tier Chart and Criteria – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

8. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Herzuma® (Trastuzumab-pkrb), Kanjinti™ (Trastuzumab-anns), Ontruzant® (Trastuzumab-dttb), Piqray® (Alpelisib), Talzenna® (Talazoparib), and Trazimera™ (Trastuzumab-qyyp) – See Appendix F

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Breast Cancer Medications
- D. Prior Authorization of Breast Cancer Medications
- E. Market News and Updates
- F. Product Summaries
- G. Recommendations
- H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

9. Annual Review of Prostate Cancer Medications and 30-Day Notice to Prior Authorize Nubeqa™ (Darolutamide) – See Appendix G

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Prostate Cancer Medications
- D. Prior Authorization of Prostate Cancer Medications
- E. Market News and Updates
- F. Nubeqa™ (Darolutamide) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Prostate Cancer Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. Action Item – Annual Review of Crysvida® (Burosumab-twza) – See Appendix H

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Crysvida® (Burosumab-twza)
- D. Prior Authorization of Crysvida® (Burosumab-twza)
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

11. Annual Review of Antihyperlipidemics and 30-Day Notice to Prior Authorize Welchol® (Colesevelam Chewable Bar) and Ezallor™ Sprinkle (Rosuvastatin Capsule) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Antihyperlipidemics
- C. Prior Authorization of Antihyperlipidemics
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Antihyperlipidemics

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

12. 30-Day Notice to Prior Authorize Sorilux® (Calcipotriene 0.005% Foam) – See Appendix J

- A. Introduction
- B. Sorilux® (Calcipotriene 0.005% Foam) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

13. Annual Review of Synagis® (Palivizumab) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Synagis® (Palivizumab)
- C. Prior Authorization of Synagis® (Palivizumab)
- D. Season Comparison
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

14. Annual Review of Sickle Cell Disease (SCD) Medications – See Appendix L

- A. Current Prior Authorization Criteria

- B. Utilization of SCD Medications
- C. Prior Authorization of SCD Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of SCD Medications

Non-Presentation; Questions Only:

15. Industry News and Updates – See Appendix M

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

16. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix N

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

17. Future Business* (Upcoming Product and Class Reviews)

- A. Turalio™ (Pexidartinib)
- B. Hepatitis C Medications
- C. Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Medications
- D. Cystic Fibrosis Medications
- E. Signifor® LAR (Pasireotide)
- F. Amyloidosis Medications
- G. Various Antibiotics

**Future business subject to change.*

18. Adjournment